THERAPY DOSSIER · th-94d5ef026add

Allogeneic bone marrow stromal cells from GFP-transgenic Sprague-Dawley rats, phenotype CD90 positive, CD29 positive, CD34 negative, CD11b negative

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 4

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02448849 ↗Injury indicationPHASE2/PHASE3unknown

Use of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Combination With Platelet Lysate Product for Human Long Bone Nonunion Treatment, A Phase 2-3 Clinical Trial

Bone Fracture

Enrolment: 60 · Results not recorded

NCT01557543 ↗PHASE1terminated

Preliminary Assessment of Direct Intra-Myocardial Injection of Autologous Bone Marrow-derived Stromal Cells on Patients Undergoing Revascularization for CAD With Depressed Left Ventricular Function

Heart Disease · Ischemic Heart Disease · Coronary Artery Disease

Enrolment: 24 · Results not recorded

NCT01851343 ↗PHASE1terminated

An Open-Label, Phase 1 Study to Assess the Safety and Tolerability of Bone Marrow Stromal Cell Infusion for the Treatment of Moderate to Severe Inflammatory Bowel Disease

Inflammatory Bowel Disease

Enrolment: 8 · Results not recorded

NCT01686139 ↗PHASE1unknown

Phase 1 Study: Treatment of Patients With Diabetic Foot Complications With Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (ABMD-MSC)

Type I Diabetes Mellitus With Ulcer · Type II Diabetes Mellitus With Ulcer

Enrolment: 12 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24039961 ↗2013Reported benefit

Effects of bone marrow stromal cell transplantation through CSF on the subacute and chronic spinal cord injury in rats.

RatSpinal cord injuryContusionSprague-Dawley, with donor cells from GFP-transgenic Sprague-Dawley ratsFemale recipientsn = 99 rats in total with 10 deaths; 1 week group 30 treated an…Injection into the cerebrospinal fluid through the fourth ventricle, using a 29-gauge needle inserted 6 mm from the cerebellar surface through a skull pore 3.5 mm caudal to lambdaCell suspension of 50 microlitres of phosphate buffered sal…First injection at 1, 2 or 4 weeks after injury, corresponding to subacute and…

Model: Contusion spinal cord injury after Th8 to Th9 laminectomy under isoflurane anaesthesia, using the New York University impactor with a 10 g weight dropped from 7.5 cm

Bone marrow stromal cell infusion into the cerebrospinal fluid improved BBB scores at all three treatment times, reduced cavity volume and increased axon density in the astrocyte-devoid epicentre (291.6 plus or minus 64.7 versus 65.5 plus or minus 15.3 per 0.25 square mm), despite no long-term cell…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…